GlaxoSmithKline Intellectual Property Development Limited
发明人:
Paul-Peter TAK
申请号：
US16829252
公开号：
US20200231666A1
申请日:
2020.03.25
申请国别(地区):
US
年份:
2020
代理人:
摘要：
An antibody antagonist of GM-CSF for use in the treatment of a patient suffering from rheumatoid arthritis (RA), wherein said antibody is administered to said patient according to the following treatment regimen:i. a first period wherein the antibody is administered once a week； andii. a second period wherein the antibody is administered every other week and then ceased once said patient has sustained remission for a continuous period of at least two months.
